Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Фактор роста фибробластов 21 (FGF21): диагностические, прогностические и терапевтические аспекты при сердечной недостаточности
Фактор роста фибробластов 21 (FGF21): диагностические, прогностические и терапевтические аспекты при сердечной недостаточности
Алиева А.М., Теплова Н.В., Резник Е.В., Байкова И.Е., Хаджиева Н.Х., Воронкова К.В., Ковтюх И.В., Валиев Р.К., Котикова И.А., Никитин И.Г. Фактор роста фибробластов 21 (FGF21): диагностические, прогностические и терапевтические аспекты при сердечной недостаточности. Consilium Medicum. 2024;26(1):40–44. DOI: 10.26442/20751753.2024.1.202593
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2024 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Хроническая сердечная недостаточность (ХСН) представляет собой глобальную медицинскую, социальную и экономическую проблему. В настоящее время продолжаются поиск и изучение новых биомаркеров, способных обеспечить раннюю диагностику ХСН, служить лабораторным инструментом оценки эффективности проводимого лечения или использоваться в качестве прогностических маркеров и критериев стратификации риска. Интерес ученых сосредоточен, в частности, на изучении роли фактора роста фибробластов 21 (FGF21) при ХСН. Появляется все больше данных, подчеркивающих ценность FGF21 в качестве нового маркера для диагностики и оценки прогноза у больных с ХСН. Роль FGF21 при ХСН очень интересна и вследствие его кардиопротективных аспектов. Окончательное подтверждение диагностической, прогностической и терапевтической роли FGF21 будет получено в результате исследований в перспективе.
Ключевые слова: биологический маркер, фактор роста фибробластов 21, хроническая сердечная недостаточность
Keywords: biological marker, fibroblast growth factor 21, chronic heart failure
Ключевые слова: биологический маркер, фактор роста фибробластов 21, хроническая сердечная недостаточность
________________________________________________
Keywords: biological marker, fibroblast growth factor 21, chronic heart failure
Полный текст
Список литературы
1. Lee J, Oh O, Park DI, et al. Scoping review of measures of comorbidities in heart failure. J Cardiovasc Nurs. 2024;39(1):5-17. DOI:10.1097/JCN.0000000000001016
2. Doherty DJ, Docherty KF, Gardner RS. Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure. Heart. 2024;110(7):466-75. DOI:10.1136/heartjnl-2022-322164
3. Калюжин В.В., Тепляков А.Т., Черногорюк Г.Э., и др. Хроническая сердечная недостаточность: синдром или заболевание? Бюллетень сибирской медицины. 2020;19(1):134-9 [Kalyuzhin VV, Teplyakov AT, Chernogoryuk GE, et al. Chronic heart failure: syndrome or disease? Bulletin of Siberian Medicine. 2020;19(1):134-9 (in Russian)]. DOI:10.20538/1682-0363-2020-1-134-139
4. Kretzschmar T, Westphal J, Neugebauer S, et al. Metabolic profiling identifies 1-MetHis and 3-IPA as potential diagnostic biomarkers for patients with acute and chronic heart failure with reduced ejection fraction. Circ Heart Fail. 2024;17(1):e010813. DOI:10.1161/CIRCHEARTFAILURE.123.010813
5. Голухова Е.З., Теряева Н.Б., Алиева А.М. Натрийуретические пептиды – маркеры и факторы прогноза при хронической сердечной недостаточности. Креативная кардиология.2007;1-2:126-36 [Golukhova EZ, Teryaeva NB, Alieva AM. Natriuretic peptides: markers and prognostic factors in chronic heart failure. Creative Cardiology.
2007;1-2:126-36 (in Russian)].
6. Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью. Кардиология и сердечно-сосудистая хирургия. 2007;47(1):45-51 [Golukhova EZ, Alieva AM. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. The Russian Journal of Cardiology & Cardiovascular Surgery. 2007;47(1):45-51 (in Russian)].
7. Goutam RS, Kumar V, Lee U, Kim J. Exploring the structural and functional diversity among FGF signals: A comparative study of human, mouse, and xenopus FGF ligands in embryonic development and cancer pathogenesis. Int J Mol Sci. 2023;24(8):7556. DOI:10.3390/ijms24087556
8. Yan J, Nie Y, Cao J, et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med. 2021;8:655575. DOI:10.3389/fcvm.2021.655575
9. Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Dis Transl Med. 2022;8(1):19-25. DOI:10.1016/j.cdtm.2021.08.005
10. Badakhshi Y, Jin T. Current understanding and controversies on the clinical implications of fibroblast growth factor 21. Crit Rev Clin Lab Sci. 2021;58(5):311-28. DOI:10.1080/10408363.2020.1864278
11. Falamarzi K, Malekpour M, Tafti MF, et al. The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne). 2022;9:967375. DOI:10.3389/fmed.2022.967375
12. Алиева А.М., Байкова И.Е., Резник Е.В., и др. Фактор роста фибробластов 21-новый инструмент в многокомпонентной оценке сердечно-сосудистых заболеваний. Российский медицинский журнал. 2022;28(1):75-88 [Alieva AM, Baikova IE, Reznik EV, et al. Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases. Russian Medicine. 2022;28(1):75-88 (in Russian)]. DOI:10.17816/medjrf108900
13. Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol (Lausanne). 2023;14:1150222. DOI:10.3389/fendo.2023.1150222
14. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-35. DOI:10.1172/JCI23606
15. Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019;10:37. DOI:10.3389/fphys.2019.00037
16. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790-7. DOI:10.1016/j.cmet.2013.03.019
17. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470-8. DOI:10.2337/db05-1435
18. Rosales-Soto G, Diaz-Vegas A, Casas M, et al. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol. 2020:JME-19-0210.R2. DOI:10.1530/JME-19-0210
19. Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev. 2023;28(1):261-72. DOI:10.1007/s10741-022-10268-0
20. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59(7):1817-24. DOI:10.2337/db09-1878
21. Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20(4):670-7. DOI:10.1016/j.cmet.2014.07.012
22. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781-9. DOI:10.2337/db10-0193
23. Geng L, Liao B, Jin L, et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep. 2019;26(10):2738-52.e4. DOI:10.1016/j.celrep.2019.02.014
24. Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019. DOI:10.1038/ncomms3019
25. Planavila A, Redondo-Angulo I, Ribas F, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106(1):19-31. DOI:10.1093/cvr/cvu263
26. Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun. 2015;459(1):124-30. DOI:10.1016/j.bbrc.2015.02.081
27. Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and cardiac physiopathology. Front Endocrinol (Lausanne). 2015;6:133. DOI:10.3389/fendo.2015.00133
28. Rius-Pérez S, Torres-Cuevas I, Millán I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696. DOI:10.1155/2020/1452696
29. Pan X, Shao Y, Wu F, et al. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice. Cell Metab. 2018;27(6):1323-37.e5. DOI:10.1016/j.cmet.2018.04.002
30. Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep. 2017;19(4):28.
DOI:10.1007/s11906-017-0730-5
31. Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. DOI:10.3389/fendo.2023.1220426
32. Wang N, Xu TY, Zhang X, et al. Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes. Int Immunopharmacol. 2018;56:301-9. DOI:10.1016/j.intimp.2018.01.048
33. Furukawa N, Koitabashi N, Matsui H, et al. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism. Heart Vessels. 2021;36(1):136-46. DOI:10.1007/s00380-020-01711-z
34. Chou RH, Huang PH, Hsu CY, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6:33953. DOI:10.1038/srep33953
35. Fan L, Gu L, Yao Y, Ma G. Elevated serum fibroblast growth factor 21 is relevant to heart failure patients with reduced ejection fraction. Comput Math Methods Med. 2022;2022:7138776. DOI:10.1155/2022/7138776
36. Sommakia S, Almaw NH, Lee SH, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022;15(3):e008910. DOI:10.1161/CIRCHEARTFAILURE.121.008910
37. Ianoș RD, Pop C, Iancu M, et al. Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus. Diagnostics (Basel). 2021;11(9):1577. DOI:10.3390/diagnostics11091577
38. Gu L, Jiang W, Zheng R, et al. Fibroblast growth factor 21 correlates with the prognosis of dilated cardiomyopathy. Cardiology. 2021;146(1):27-33. DOI:10.1159/000509239
39. Gu L, Jiang W, Jiang W, et al. Elevated serum FGF21 levels predict heart failure during hospitalization of STEMI patients after emergency percutaneous coronary intervention. Peer J. 2023;11:e14855. DOI:10.7717/peerj.14855
40. Yan B, Ma S, Yan C, Han Y. Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2023;14:1108234. DOI:10.3389/fendo.2023.1108234
2. Doherty DJ, Docherty KF, Gardner RS. Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure. Heart. 2024;110(7):466-75. DOI:10.1136/heartjnl-2022-322164
3. Kalyuzhin VV, Teplyakov AT, Chernogoryuk GE, et al. Chronic heart failure: syndrome or disease? Bulletin of Siberian Medicine. 2020;19(1):134-9 (in Russian).
DOI:10.20538/1682-0363-2020-1-134-139
4. Kretzschmar T, Westphal J, Neugebauer S, et al. Metabolic profiling identifies 1-MetHis and 3-IPA as potential diagnostic biomarkers for patients with acute and chronic heart failure with reduced ejection fraction. Circ Heart Fail. 2024;17(1):e010813. DOI:10.1161/CIRCHEARTFAILURE.123.010813
5. Golukhova EZ, Teryaeva NB, Alieva AM. Natriuretic peptides: markers and prognostic factors in chronic heart failure. Creative Cardiology. 2007;1-2:126-36 (in Russian).
6. Golukhova EZ, Alieva AM. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. The Russian Journal of Cardiology & Cardiovascular Surgery. 2007;47(1):45-51 (in Russian).
7. Goutam RS, Kumar V, Lee U, Kim J. Exploring the structural and functional diversity among FGF signals: A comparative study of human, mouse, and xenopus FGF ligands in embryonic development and cancer pathogenesis. Int J Mol Sci. 2023;24(8):7556. DOI:10.3390/ijms24087556
8. Yan J, Nie Y, Cao J, et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med. 2021;8:655575. DOI:10.3389/fcvm.2021.655575
9. Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Dis Transl Med. 2022;8(1):19-25. DOI:10.1016/j.cdtm.2021.08.005
10. Badakhshi Y, Jin T. Current understanding and controversies on the clinical implications of fibroblast growth factor 21. Crit Rev Clin Lab Sci. 2021;58(5):311-28. DOI:10.1080/10408363.2020.1864278
11. Falamarzi K, Malekpour M, Tafti MF, et al. The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne). 2022;9:967375. DOI:10.3389/fmed.2022.967375
12. Alieva AM, Baikova IE, Reznik EV, et al. Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases. Russian Medicine. 2022;28(1):75-88 (in Russian). DOI:10.17816/medjrf108900
13. Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol (Lausanne). 2023;14:1150222. DOI:10.3389/fendo.2023.1150222
14. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-35. DOI:10.1172/JCI23606
15. Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019;10:37. DOI:10.3389/fphys.2019.00037
16. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790-7. DOI:10.1016/j.cmet.2013.03.019
17. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470-8. DOI:10.2337/db05-1435
18. Rosales-Soto G, Diaz-Vegas A, Casas M, et al. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol. 2020:JME-19-0210.R2. DOI:10.1530/JME-19-0210
19. Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev. 2023;28(1):261-72. DOI:10.1007/s10741-022-10268-0
20. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59(7):1817-24. DOI:10.2337/db09-1878
21. Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20(4):670-7. DOI:10.1016/j.cmet.2014.07.012
22. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781-9. DOI:10.2337/db10-0193
23. Geng L, Liao B, Jin L, et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep. 2019;26(10):2738-52.e4. DOI:10.1016/j.celrep.2019.02.014
24. Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019. DOI:10.1038/ncomms3019
25. Planavila A, Redondo-Angulo I, Ribas F, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106(1):19-31. DOI:10.1093/cvr/cvu263
26. Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun. 2015;459(1):124-30. DOI:10.1016/j.bbrc.2015.02.081
27. Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and cardiac physiopathology. Front Endocrinol (Lausanne). 2015;6:133. DOI:10.3389/fendo.2015.00133
28. Rius-Pérez S, Torres-Cuevas I, Millán I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696. DOI:10.1155/2020/1452696
29. Pan X, Shao Y, Wu F, et al. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice. Cell Metab. 2018;27(6):1323-37.e5. DOI:10.1016/j.cmet.2018.04.002
30. Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep. 2017;19(4):28.
DOI:10.1007/s11906-017-0730-5
31. Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. DOI:10.3389/fendo.2023.1220426
32. Wang N, Xu TY, Zhang X, et al. Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes. Int Immunopharmacol. 2018;56:301-9. DOI:10.1016/j.intimp.2018.01.048
33. Furukawa N, Koitabashi N, Matsui H, et al. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism. Heart Vessels. 2021;36(1):136-46. DOI:10.1007/s00380-020-01711-z
34. Chou RH, Huang PH, Hsu CY, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6:33953. DOI:10.1038/srep33953
35. Fan L, Gu L, Yao Y, Ma G. Elevated serum fibroblast growth factor 21 is relevant to heart failure patients with reduced ejection fraction. Comput Math Methods Med. 2022;2022:7138776. DOI:10.1155/2022/7138776
36. Sommakia S, Almaw NH, Lee SH, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022;15(3):e008910. DOI:10.1161/CIRCHEARTFAILURE.121.008910
37. Ianoș RD, Pop C, Iancu M, et al. Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus. Diagnostics (Basel). 2021;11(9):1577. DOI:10.3390/diagnostics11091577
38. Gu L, Jiang W, Zheng R, et al. Fibroblast growth factor 21 correlates with the prognosis of dilated cardiomyopathy. Cardiology. 2021;146(1):27-33. DOI:10.1159/000509239
39. Gu L, Jiang W, Jiang W, et al. Elevated serum FGF21 levels predict heart failure during hospitalization of STEMI patients after emergency percutaneous coronary intervention. Peer J. 2023;11:e14855. DOI:10.7717/peerj.14855
40. Yan B, Ma S, Yan C, Han Y. Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2023;14:1108234. DOI:10.3389/fendo.2023.1108234
2. Doherty DJ, Docherty KF, Gardner RS. Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure. Heart. 2024;110(7):466-75. DOI:10.1136/heartjnl-2022-322164
3. Калюжин В.В., Тепляков А.Т., Черногорюк Г.Э., и др. Хроническая сердечная недостаточность: синдром или заболевание? Бюллетень сибирской медицины. 2020;19(1):134-9 [Kalyuzhin VV, Teplyakov AT, Chernogoryuk GE, et al. Chronic heart failure: syndrome or disease? Bulletin of Siberian Medicine. 2020;19(1):134-9 (in Russian)]. DOI:10.20538/1682-0363-2020-1-134-139
4. Kretzschmar T, Westphal J, Neugebauer S, et al. Metabolic profiling identifies 1-MetHis and 3-IPA as potential diagnostic biomarkers for patients with acute and chronic heart failure with reduced ejection fraction. Circ Heart Fail. 2024;17(1):e010813. DOI:10.1161/CIRCHEARTFAILURE.123.010813
5. Голухова Е.З., Теряева Н.Б., Алиева А.М. Натрийуретические пептиды – маркеры и факторы прогноза при хронической сердечной недостаточности. Креативная кардиология.2007;1-2:126-36 [Golukhova EZ, Teryaeva NB, Alieva AM. Natriuretic peptides: markers and prognostic factors in chronic heart failure. Creative Cardiology.
2007;1-2:126-36 (in Russian)].
6. Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью. Кардиология и сердечно-сосудистая хирургия. 2007;47(1):45-51 [Golukhova EZ, Alieva AM. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. The Russian Journal of Cardiology & Cardiovascular Surgery. 2007;47(1):45-51 (in Russian)].
7. Goutam RS, Kumar V, Lee U, Kim J. Exploring the structural and functional diversity among FGF signals: A comparative study of human, mouse, and xenopus FGF ligands in embryonic development and cancer pathogenesis. Int J Mol Sci. 2023;24(8):7556. DOI:10.3390/ijms24087556
8. Yan J, Nie Y, Cao J, et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med. 2021;8:655575. DOI:10.3389/fcvm.2021.655575
9. Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Dis Transl Med. 2022;8(1):19-25. DOI:10.1016/j.cdtm.2021.08.005
10. Badakhshi Y, Jin T. Current understanding and controversies on the clinical implications of fibroblast growth factor 21. Crit Rev Clin Lab Sci. 2021;58(5):311-28. DOI:10.1080/10408363.2020.1864278
11. Falamarzi K, Malekpour M, Tafti MF, et al. The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne). 2022;9:967375. DOI:10.3389/fmed.2022.967375
12. Алиева А.М., Байкова И.Е., Резник Е.В., и др. Фактор роста фибробластов 21-новый инструмент в многокомпонентной оценке сердечно-сосудистых заболеваний. Российский медицинский журнал. 2022;28(1):75-88 [Alieva AM, Baikova IE, Reznik EV, et al. Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases. Russian Medicine. 2022;28(1):75-88 (in Russian)]. DOI:10.17816/medjrf108900
13. Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol (Lausanne). 2023;14:1150222. DOI:10.3389/fendo.2023.1150222
14. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-35. DOI:10.1172/JCI23606
15. Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019;10:37. DOI:10.3389/fphys.2019.00037
16. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790-7. DOI:10.1016/j.cmet.2013.03.019
17. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470-8. DOI:10.2337/db05-1435
18. Rosales-Soto G, Diaz-Vegas A, Casas M, et al. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol. 2020:JME-19-0210.R2. DOI:10.1530/JME-19-0210
19. Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev. 2023;28(1):261-72. DOI:10.1007/s10741-022-10268-0
20. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59(7):1817-24. DOI:10.2337/db09-1878
21. Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20(4):670-7. DOI:10.1016/j.cmet.2014.07.012
22. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781-9. DOI:10.2337/db10-0193
23. Geng L, Liao B, Jin L, et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep. 2019;26(10):2738-52.e4. DOI:10.1016/j.celrep.2019.02.014
24. Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019. DOI:10.1038/ncomms3019
25. Planavila A, Redondo-Angulo I, Ribas F, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106(1):19-31. DOI:10.1093/cvr/cvu263
26. Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun. 2015;459(1):124-30. DOI:10.1016/j.bbrc.2015.02.081
27. Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and cardiac physiopathology. Front Endocrinol (Lausanne). 2015;6:133. DOI:10.3389/fendo.2015.00133
28. Rius-Pérez S, Torres-Cuevas I, Millán I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696. DOI:10.1155/2020/1452696
29. Pan X, Shao Y, Wu F, et al. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice. Cell Metab. 2018;27(6):1323-37.e5. DOI:10.1016/j.cmet.2018.04.002
30. Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep. 2017;19(4):28.
DOI:10.1007/s11906-017-0730-5
31. Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. DOI:10.3389/fendo.2023.1220426
32. Wang N, Xu TY, Zhang X, et al. Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes. Int Immunopharmacol. 2018;56:301-9. DOI:10.1016/j.intimp.2018.01.048
33. Furukawa N, Koitabashi N, Matsui H, et al. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism. Heart Vessels. 2021;36(1):136-46. DOI:10.1007/s00380-020-01711-z
34. Chou RH, Huang PH, Hsu CY, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6:33953. DOI:10.1038/srep33953
35. Fan L, Gu L, Yao Y, Ma G. Elevated serum fibroblast growth factor 21 is relevant to heart failure patients with reduced ejection fraction. Comput Math Methods Med. 2022;2022:7138776. DOI:10.1155/2022/7138776
36. Sommakia S, Almaw NH, Lee SH, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022;15(3):e008910. DOI:10.1161/CIRCHEARTFAILURE.121.008910
37. Ianoș RD, Pop C, Iancu M, et al. Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus. Diagnostics (Basel). 2021;11(9):1577. DOI:10.3390/diagnostics11091577
38. Gu L, Jiang W, Zheng R, et al. Fibroblast growth factor 21 correlates with the prognosis of dilated cardiomyopathy. Cardiology. 2021;146(1):27-33. DOI:10.1159/000509239
39. Gu L, Jiang W, Jiang W, et al. Elevated serum FGF21 levels predict heart failure during hospitalization of STEMI patients after emergency percutaneous coronary intervention. Peer J. 2023;11:e14855. DOI:10.7717/peerj.14855
40. Yan B, Ma S, Yan C, Han Y. Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2023;14:1108234. DOI:10.3389/fendo.2023.1108234
________________________________________________
2. Doherty DJ, Docherty KF, Gardner RS. Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure. Heart. 2024;110(7):466-75. DOI:10.1136/heartjnl-2022-322164
3. Kalyuzhin VV, Teplyakov AT, Chernogoryuk GE, et al. Chronic heart failure: syndrome or disease? Bulletin of Siberian Medicine. 2020;19(1):134-9 (in Russian).
DOI:10.20538/1682-0363-2020-1-134-139
4. Kretzschmar T, Westphal J, Neugebauer S, et al. Metabolic profiling identifies 1-MetHis and 3-IPA as potential diagnostic biomarkers for patients with acute and chronic heart failure with reduced ejection fraction. Circ Heart Fail. 2024;17(1):e010813. DOI:10.1161/CIRCHEARTFAILURE.123.010813
5. Golukhova EZ, Teryaeva NB, Alieva AM. Natriuretic peptides: markers and prognostic factors in chronic heart failure. Creative Cardiology. 2007;1-2:126-36 (in Russian).
6. Golukhova EZ, Alieva AM. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. The Russian Journal of Cardiology & Cardiovascular Surgery. 2007;47(1):45-51 (in Russian).
7. Goutam RS, Kumar V, Lee U, Kim J. Exploring the structural and functional diversity among FGF signals: A comparative study of human, mouse, and xenopus FGF ligands in embryonic development and cancer pathogenesis. Int J Mol Sci. 2023;24(8):7556. DOI:10.3390/ijms24087556
8. Yan J, Nie Y, Cao J, et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med. 2021;8:655575. DOI:10.3389/fcvm.2021.655575
9. Shao W, Jin T. Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Dis Transl Med. 2022;8(1):19-25. DOI:10.1016/j.cdtm.2021.08.005
10. Badakhshi Y, Jin T. Current understanding and controversies on the clinical implications of fibroblast growth factor 21. Crit Rev Clin Lab Sci. 2021;58(5):311-28. DOI:10.1080/10408363.2020.1864278
11. Falamarzi K, Malekpour M, Tafti MF, et al. The role of FGF21 and its analogs on liver associated diseases. Front Med (Lausanne). 2022;9:967375. DOI:10.3389/fmed.2022.967375
12. Alieva AM, Baikova IE, Reznik EV, et al. Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases. Russian Medicine. 2022;28(1):75-88 (in Russian). DOI:10.17816/medjrf108900
13. Aaldijk AS, Verzijl CRC, Jonker JW, Struik D. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. Front Endocrinol (Lausanne). 2023;14:1150222. DOI:10.3389/fendo.2023.1150222
14. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627-35. DOI:10.1172/JCI23606
15. Cuevas-Ramos D, Mehta R, Aguilar-Salinas CA. Fibroblast growth factor 21 and browning of white adipose tissue. Front Physiol. 2019;10:37. DOI:10.3389/fphys.2019.00037
16. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790-7. DOI:10.1016/j.cmet.2013.03.019
17. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470-8. DOI:10.2337/db05-1435
18. Rosales-Soto G, Diaz-Vegas A, Casas M, et al. Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers. J Mol Endocrinol. 2020:JME-19-0210.R2. DOI:10.1530/JME-19-0210
19. Tucker W, Tucker B, Rye KA, Ong KL. Fibroblast growth factor 21 in heart failure. Heart Fail Rev. 2023;28(1):261-72. DOI:10.1007/s10741-022-10268-0
20. Sarruf DA, Thaler JP, Morton GJ, et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes. 2010;59(7):1817-24. DOI:10.2337/db09-1878
21. Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20(4):670-7. DOI:10.1016/j.cmet.2014.07.012
22. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781-9. DOI:10.2337/db10-0193
23. Geng L, Liao B, Jin L, et al. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep. 2019;26(10):2738-52.e4. DOI:10.1016/j.celrep.2019.02.014
24. Planavila A, Redondo I, Hondares E, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun. 2013;4:2019. DOI:10.1038/ncomms3019
25. Planavila A, Redondo-Angulo I, Ribas F, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106(1):19-31. DOI:10.1093/cvr/cvu263
26. Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun. 2015;459(1):124-30. DOI:10.1016/j.bbrc.2015.02.081
27. Planavila A, Redondo-Angulo I, Villarroya F. FGF21 and cardiac physiopathology. Front Endocrinol (Lausanne). 2015;6:133. DOI:10.3389/fendo.2015.00133
28. Rius-Pérez S, Torres-Cuevas I, Millán I, et al. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696. DOI:10.1155/2020/1452696
29. Pan X, Shao Y, Wu F, et al. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice. Cell Metab. 2018;27(6):1323-37.e5. DOI:10.1016/j.cmet.2018.04.002
30. Huang Z, Xu A, Cheung BMY. The potential role of fibroblast growth factor 21 in lipid metabolism and hypertension. Curr Hypertens Rep. 2017;19(4):28.
DOI:10.1007/s11906-017-0730-5
31. Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1220426. DOI:10.3389/fendo.2023.1220426
32. Wang N, Xu TY, Zhang X, et al. Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes. Int Immunopharmacol. 2018;56:301-9. DOI:10.1016/j.intimp.2018.01.048
33. Furukawa N, Koitabashi N, Matsui H, et al. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism. Heart Vessels. 2021;36(1):136-46. DOI:10.1007/s00380-020-01711-z
34. Chou RH, Huang PH, Hsu CY, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6:33953. DOI:10.1038/srep33953
35. Fan L, Gu L, Yao Y, Ma G. Elevated serum fibroblast growth factor 21 is relevant to heart failure patients with reduced ejection fraction. Comput Math Methods Med. 2022;2022:7138776. DOI:10.1155/2022/7138776
36. Sommakia S, Almaw NH, Lee SH, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022;15(3):e008910. DOI:10.1161/CIRCHEARTFAILURE.121.008910
37. Ianoș RD, Pop C, Iancu M, et al. Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus. Diagnostics (Basel). 2021;11(9):1577. DOI:10.3390/diagnostics11091577
38. Gu L, Jiang W, Zheng R, et al. Fibroblast growth factor 21 correlates with the prognosis of dilated cardiomyopathy. Cardiology. 2021;146(1):27-33. DOI:10.1159/000509239
39. Gu L, Jiang W, Jiang W, et al. Elevated serum FGF21 levels predict heart failure during hospitalization of STEMI patients after emergency percutaneous coronary intervention. Peer J. 2023;11:e14855. DOI:10.7717/peerj.14855
40. Yan B, Ma S, Yan C, Han Y. Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis. Front Endocrinol (Lausanne). 2023;14:1108234. DOI:10.3389/fendo.2023.1108234
Авторы
А.М. Алиева*1, Н.В. Теплова1, Е.В. Резник1, И.Е. Байкова1, Н.Х. Хаджиева2, К.В. Воронкова1, И.В. Ковтюх1, Р.К. Валиев3, И.А. Котикова1, И.Г. Никитин1
1ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2Клиника Генетики и ДНК «МедЭстет», Москва, Россия;
3ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия
*amisha_alieva@mail.ru
1Pirogov Russian National Research Medical University, Moscow, Russia;
2MedEstet Genetics and DNA Clinic, Moscow, Russia;
3Loginov Moscow Clinical Scientific Center, Moscow, Russia
*amisha_alieva@mail.ru
1ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2Клиника Генетики и ДНК «МедЭстет», Москва, Россия;
3ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия
*amisha_alieva@mail.ru
________________________________________________
1Pirogov Russian National Research Medical University, Moscow, Russia;
2MedEstet Genetics and DNA Clinic, Moscow, Russia;
3Loginov Moscow Clinical Scientific Center, Moscow, Russia
*amisha_alieva@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.